Supplementary Material for: Hepatic fibrosis evaluated in patients with type 2 diabetes with and without chronic kidney disease

Background. Non-alcoholic fatty liver disease (NAFLD), and particularly liver fibrosis, has been suggested as a risk factor of chronic kidney disease (CKD). Given that NAFLD affects every fourth person globally, better insight is needed. Our aim was to investigate the association between hepatic fibrosis and CKD in patients with type 2 diabetes and to compare different methods for diagnosing liver fibrosis in this study population. Methods. Cross-sectional study including patients with type 2 diabetes with CKD Stages 3–5 (N=50) or without CKD (N=50). CKD was defined as eGFR <60 mL/min/1.73 m2 with or without proteinuria. Three methods were used to detect significant liver fibrosis defined as either ≥8 kilopascal measured by transient elastography (FibroScan®), fibrosis-4 (FIB-4) score ≥2.67 or NAFLD fibrosis score (NFS) >0.675. Results. Significant liver fibrosis was found in 38% and 28% of the patients with and without CKD, respectively, using at least one of the three methods. Both FIB-4 score and NFS were significantly higher in patients with CKD (P<0.0009 and P<0.0001, respectively), although insignificant after adjustments for age, sex, BMI, and duration of diabetes. In patients without CKD, a significant association between steatosis and fibrosis was observed (P=0.0007). Discussion/ Conclusion. Our data do not support any strong independent association between liver fibrosis and established CKD as assessed by FibroScan, FIB-4 score and NFS, respectively.